Immune-Onc’s lead program, an antibody targeting an immune inhibitory receptor, is being explored as a potential candidate in the treatment of acute myeloid leukemia (AML) and other cancers.
Ablynx’s proprietary Nanobody platform allows for the rapid generation and large-scale production of novel biological therapeutics that have potential in a wide range of human diseases.
Abraxis develops, manufactures, and markets rapid environmental, food, and life sciences test systems, including immunochemistry products and methods, to meet the testing needs of research and ...
Aduro’s three proprietary technology platforms (Live, Attenuated Double-Deleted Listeria (LADD), STING Pathway Activators, and B-select monoclonal antibodies) have the potential to transform the ...
Agenus uses the power of the immune system to develop innovative product candidates against cancer. The company has assembled a broad portfolio of antibodies including checkpoint inhibitors and ...
Alder BioPharmaceuticals is developing monoclonal antibody therapeutics for the treatment of migraine, Cushing’s disease, Congenital Adrenal Hyperplasia and autoimmune and inflammatory diseases.
Biologics. Amgen makes several therapeutic drugs that target serious disease. Many are derived from engineered monoclonal antibodies. Some target immune receptors.
A biopharmaceutical company that focuses on Cardiovascular and Metabolic diseases, Oncology, and Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal diseases, ...
